Cytokinetics 3Q 2026: Revenue $47.6M, Net loss $190.1M, EPS $(1.37) — 10-Q Summary
Cytokinetics reported 3Q 2026 revenue of $47.6M, up from $1.9M a year earlier, driven by $44.5M in MYQORZO product revenue. Net loss narrowed to $190.1M from $306.2M. MYQORZO launched in Germany and China, with EU, UK, and Canada approvals. ACACIA-HCM study met endpoints, and FDA decisions on expanded MYQORZO label and CK-089 trials are pending.
How this was made
The 30-second read
Why it matters
The earnings beat on revenue and loss narrowing could attract short‑term buying, but the company's valuation remains tied to regulatory outcomes for MYQORZO and other pipeline candidates.
Market read
Primary earnings disclosure for a micro‑cap biotech; relevance mainly to sector traders and investors in CYTK.
What to watch
Pending FDA supplemental application and label expansion could delay further upside if not approved.
Background
Cytokinetics (CYTK) is a biotech focused on cardiac muscle therapeutics. The Q3 2026 filing is its first public release of the quarter's financials.
Ticker impact
Q3 2026 10‑Q shows revenue jump to $47.6M and loss narrowing to $190.1M, first public disclosure of these results.
potential upside as investors price in higher revenue and narrowed loss
The company reported a 2400% YoY revenue increase and a 38% reduction in net loss, which typically supports a bullish reaction in a micro‑cap biotech.
Market effects
Improved HCM data may boost sentiment toward cardiology biotech peers.
U.S. biotech sector could see modest buying pressure.
Limited to niche cardiology drug market; no broad macro effect.
Counterpoint
The revenue growth is driven by a single product; reliance on MYQORZO may expose the stock to future regulatory or competitive risk.
Key entities
- companyCytokinetics
Biotech developer of MYQORZO and other cardiac therapeutics.
- productMYQORZO
Cardiac drug generating the bulk of Q3 revenue.
